<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:arxiv="http://arxiv.org/schemas/atom" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title>q-bio.GN updates on arXiv.org</title>
    <link>http://rss.arxiv.org/rss/q-bio.GN</link>
    <description>q-bio.GN updates on the arXiv.org e-print archive.</description>
    <atom:link href="http://rss.arxiv.org/rss/q-bio.GN" rel="self" type="application/rss+xml"/>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <language>en-us</language>
    <lastBuildDate>Thu, 18 Sep 2025 04:01:25 +0000</lastBuildDate>
    <managingEditor>rss-help@arxiv.org</managingEditor>
    <pubDate>Thu, 18 Sep 2025 00:00:00 -0400</pubDate>
    <skipDays>
      <day>Sunday</day>
      <day>Saturday</day>
    </skipDays>
    <item>
      <title>Benchmarking Dimensionality Reduction Techniques for Spatial Transcriptomics</title>
      <link>https://arxiv.org/abs/2509.13344</link>
      <description>arXiv:2509.13344v1 Announce Type: new 
Abstract: We introduce a unified framework for evaluating dimensionality reduction techniques in spatial transcriptomics beyond standard PCA approaches. We benchmark six methods PCA, NMF, autoencoder, VAE, and two hybrid embeddings on a cholangiocarcinoma Xenium dataset, systematically varying latent dimensions ($k$=5-40) and clustering resolutions ($\rho$=0.1-1.2). Each configuration is evaluated using complementary metrics including reconstruction error, explained variance, cluster cohesion, and two novel biologically-motivated measures: Cluster Marker Coherence (CMC) and Marker Exclusion Rate (MER). Our results demonstrate distinct performance profiles: PCA provides a fast baseline, NMF maximizes marker enrichment, VAE balances reconstruction and interpretability, while autoencoders occupy a middle ground. We provide systematic hyperparameter selection using Pareto optimal analysis and demonstrate how MER-guided reassignment improves biological fidelity across all methods, with CMC scores improving by up to 12\% on average. This framework enables principled selection of dimensionality reduction methods tailored to specific spatial transcriptomics analyses.</description>
      <guid isPermaLink="false">oai:arXiv.org:2509.13344v1</guid>
      <category>q-bio.GN</category>
      <category>cs.LG</category>
      <pubDate>Thu, 18 Sep 2025 00:00:00 -0400</pubDate>
      <arxiv:announce_type>new</arxiv:announce_type>
      <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
      <dc:creator>Md Ishtyaq Mahmud, Veena Kochat, Suresh Satpati, Jagan Mohan Reddy Dwarampudi, Kunal Rai, Tania Banerjee</dc:creator>
    </item>
    <item>
      <title>PhenoGnet: A Graph-Based Contrastive Learning Framework for Disease Similarity Prediction</title>
      <link>https://arxiv.org/abs/2509.14037</link>
      <description>arXiv:2509.14037v1 Announce Type: new 
Abstract: Understanding disease similarity is critical for advancing diagnostics, drug discovery, and personalized treatment strategies. We present PhenoGnet, a novel graph-based contrastive learning framework designed to predict disease similarity by integrating gene functional interaction networks with the Human Phenotype Ontology (HPO). PhenoGnet comprises two key components: an intra-view model that separately encodes gene and phenotype graphs using Graph Convolutional Networks (GCNs) and Graph Attention Networks (GATs), and a cross view model implemented as a shared weight multilayer perceptron (MLP) that aligns gene and phenotype embeddings through contrastive learning. The model is trained using known gene phenotype associations as positive pairs and randomly sampled unrelated pairs as negatives. Diseases are represented by the mean embeddings of their associated genes and/or phenotypes, and pairwise similarity is computed via cosine similarity. Evaluation on a curated benchmark of 1,100 similar and 866 dissimilar disease pairs demonstrates strong performance, with gene based embeddings achieving an AUCPR of 0.9012 and AUROC of 0.8764, outperforming existing state of the art methods. Notably, PhenoGnet captures latent biological relationships beyond direct overlap, offering a scalable and interpretable solution for disease similarity prediction. These results underscore its potential for enabling downstream applications in rare disease research and precision medicine.</description>
      <guid isPermaLink="false">oai:arXiv.org:2509.14037v1</guid>
      <category>q-bio.GN</category>
      <category>cs.AI</category>
      <category>cs.LG</category>
      <pubDate>Thu, 18 Sep 2025 00:00:00 -0400</pubDate>
      <arxiv:announce_type>new</arxiv:announce_type>
      <dc:rights>http://arxiv.org/licenses/nonexclusive-distrib/1.0/</dc:rights>
      <dc:creator>Ranga Baminiwatte, Kazi Jewel Rana, Aaron J. Masino</dc:creator>
    </item>
  </channel>
</rss>
